**FOI Ref: 6203**

**Category(ies): Clinical - Drugs**

**Subject: Intra-Vitreal Injections or Implants**

**Date Received: 25/01/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I am analysing the usage of **intra-vitreal injections or implants** by the NHS. I would greatly appreciate if you could answer the following questions:   |
| 1. For the 4-month period from September to December 2021, how many patients has your trust treated (using intra-vitreal injections or implants) for each of the following eye conditions:* Wet Age-Related Macular Degeneration (wAMD)
* Diabetic Macular Oedema (DMO)
* Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)
* Any other eye condition
 | 4781841882 |
| 2. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from September to December 2021:* Aflibercept
* Bevacizumab
* Brolucizumab
* Dexamethasone
* Fluocinolone acetonide
* Ranibizumab
 | 7640681211057 |
| 3. Please provide the number of injections/implants by eye condition for the four-month period from September to December 2021.   |

|  |
| --- |
| **Number of Injections/Implants: Sep to Dec 2021** |
|   |   |   |   |
|   | **Eye Conditions** |
| **Treatment** | wAMD | DMO | RVO |
| Aflibercept  |  414 |  194 |  156 |
| Bevacizumab  |  0 | 0  | 0  |
| Brolucizumab   |  68 | 0  | 0  |
| Dexamethasone   |  0 | 2  | 8  |
| Fluocinolone acetonide |  0 | 1  | 0  |
| Ranibizumab  |  564 | 289  | 204  |

 |